Back Login to subscribe 🔔 Set Alert

IMRX Immuneering Corporation Class A Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	12 Health Care Stocks Moving In Monday's Intraday Session	96.06%
	Immuneering shares are trading lower. The company announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma.	40.6%
	Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma	90.2%
	Crude Oil Edges Higher; US Consumer Sentiment Falls In May	97.07%
	Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday	94.19%
	Immuneering shares are trading higher after the company announced a 17.3-month median overall survival in first-line metastatic pancreatic cancer patients treated in its Phase 2a clinical trial evaluating atebimetinib	95.09%
	Immuneering Reveals 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy; Tolerability Profile Consistent With Prior Updates; Only Two Categories Of Grade 3 Or Higher Treatment-Related Adverse Events Observed In ≥10% Of Patients, Both Chemotherapy-Related	76.41%
	Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate	65.83%